


## SARS-CoV-2-IN-13

<b>Cat. No.:</b>	HY-144770		
<b>CAS No.:</b>	56961-10-5		
<b>Molecular Formula:</b>	C <sub>13</sub> H <sub>8</sub> Cl <sub>2</sub> N <sub>2</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	327.12		
<b>Target:</b>	SARS-CoV		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 125 mg/mL (382.12 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	3.0570 mL	15.2849 mL	30.5698 mL
<b>5 mM</b>	0.6114 mL	3.0570 mL	6.1140 mL
<b>10 mM</b>	0.3057 mL	1.5285 mL	3.0570 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC<sub>50</sub> of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally<sup>[1]</sup>.

### REFERENCES

[1]. Juang YP, et al. Design, synthesis and biological evaluations of niclosamide analogues against SARS-CoV-2. Eur J Med Chem. 2022 May 5;235:114295.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA